{"prompt": "['Trelagliptin-4002', 'Page 54 of 66', 'Version 2.0', 'July 5,10', 'the study subjects and in-house records to ensure the accuracy of the CRF as necessary. The', 'completed CRF is the property of the sponsor, and the principal investigator or the investigator shall', 'not disclose the information to a third party without a written permission from the sponsor.', '12.2', 'Timing of data entry into the EDC system', 'The sponsor or the designee shall request the principal investigator and investigator to promptly', 'enter data into the EDC following enrolment of the study subject, each visit during treatment with', 'the study drug or comparative drug, completion/discontinuation of the study, and follow-up period.', '12.3', 'Storage of records', 'The principal investigator or the chief executive of the study site shall store the following materials,', 'including those specified in Section 12.1, and study-specific documents to be investigated or audited', 'by the regulatory authority and the sponsor or the designee. The documents include the list of study', 'subject ID code, medical records, clinical study worksheets (if used), original signed and dated', 'informed consent forms, the record (copy) of modification or correction on the CRF, and electric', 'copies of EDC including audit trail. The principal investigator and the chief executive of the study', 'site shall appropriately retain the material/information related to this study for at least 5 years from', 'the date of reporting the end of the study by the principal investigator, or for 3 years from the date of', 'reporting final publication of the study result, whichever date is later. However, when the sponsor', 'requires a longer storage period, the chief executive of the study site shall discuss the period and', 'methods of storage with the sponsor.', 'CONFIDENTIAL']['Trelagliptin-4002', 'Page 55 of 66', 'Version 2.0', 'July 5,10', '13.0 STATISTICAL ANALYSIS METHODS', 'The person in charge of analysis and the designee [analysis personnel, who belongs to CRO', 'independent from the sponsor] shall perform the statistical analysis. The sponsor will not be', 'involved in the statistical analysis.', '13.1', 'Statistical and analytical plans', 'The analysis personnel shall prepare a statistical analysis plan (SAP) before the acquisition of the', 'informed consent of the earliest study subject, and issue the first edition. Detailed definition of', 'endpoints and analytical methods should be specified in the SAP to deal with all the purposes of the', 'study.', '13.1.1 Analysis set', 'Two analysis sets comprising the \"Full Analysis Set (FAS)\" and the \"Safety Population\" will be', 'established. The FAS used as the main efficacy analysis set is defined as \"randomized subjects who', \"receive at least one dose of trelagliptin or daily DPP-4 inhibitor.' The safety population is defined\", 'as \"subjects who receive at least 1 dose of trelagliptin or daily DPP-4 inhibitor.\"', '13.1.2 Analysis of demographic and other baseline characteristics', 'From \"SAS\" primary study subject background items will be tabulated.', '13.1.3 Efficacy analysis', 'From FAS the following shall be analyzed.', '<Primary endpoint>', 'Change from baseline (Week 0) in total score for all question items in the DTR-QOL', 'Questionnaire at the end of the treatment period (Week 12).', '1) A comparison between the treatment groups will be carried out based on the ANCOVA model', 'using \"the change in the total score by the end of treatment [the end of the treatment period -', 'baseline (Week 0)]\" as a dependent variable; \"the total score at the baseline, the total score of', 'the DTR-QOL Questionnaire (<80% or 80%) at the start of the screening period and HbA1c', '(<8.0% or 8.0%) at the start of the screening period as covariates; and \"a treatment group\" as', 'an independent variable. The level of significance will be 5% (two-sided).', '<Secondary endpoints)', 'Efficacy endpoints:', 'CONFIDENTIAL']['Trelagliptin-4002', 'Page 56 of 66', 'Version 2.0', 'July 5, 2017', 'Changes in the total score for each factor provided through the DTR-QOL Questionnaire', '[\"Factor 1: Burden on social activities and daily activities (13 questions in all)\", Factor 2:', 'Anxiety and dissatisfaction with treatment (8 questions in all), \"Factor 3; Hypoglycemia (4', 'questions in all)\", and \"Factor 4: Treatment satisfaction (4 questions in all)\" at each assessment', 'time point.', 'Change in the total score for all questions in the DTR-QOL Questionnaire at each assessment', 'time point.', 'Change in the total score for treatment satisfaction in the DTSQ (evaluated with the score of', 'questions #1, 4, 5, 6, 7, and 8) at each assessment time point.', '1) Summary statistics [sample size, mean, standard deviation (SD), maximum, minimum and', 'quantile] and the two-sided 95% confidence interval (CI) for means per treatment group at', 'each assessment time point will be calculated to plot the changes in means and SDs. Point', 'estimates and the two-sided 95% CI for differences between the treatment groups will also', 'be calculated.', '2)', 'Changes from the baseline (Week 0) to each assessment time point will be calculated to be', 'similarly analyzed to 1) above.', '3) The analyses below carried out on the total score for each factor provided through the', 'DTR-QOL Questionnaire, and on the total score for treatment satisfaction in the DTSQ:', 'A comparison between the treatment groups will be carried out based on the ANCOVA', 'model using \"the change in the total score by the end of treatment [the end of the treatment', 'period (Week 12) - baseline (Week 0)]\" as a dependent variable; the total score at the', 'baseline (Week 0), the total score of \"the DTR-QOL Questionnaire (<80% or 80%)\" at', 'the baseline (Week 0) and \"HbAlc (<8.0% or 8.0%)\" at the baseline (Week 0) as', 'covariates; and \"a treatment group\" as an independent variable. The level of significance', 'will be 5% (two-sided). Note that the total score for all questions in the DTR-QOL is out', 'of the scope of the analysis.', '4)', 'To indicate the changes in the total scores for all questions in the DTR-QOL Questionnaire', 'and the total scores for treatment satisfaction in the DTSQ, the summary statistics and', 'two-sided 95% CI for means per treatment group will be calculated, with stratification by', 'the following factors at the start of the treatment period (Week 0):', 'Use of medication for treatment of comorbidities', 'Number of daily doses of medication for treatment of comorbidities (<2 times or >2', 'times)', 'CONFIDENTIAL']['Trelagliptin-4002', 'Page 57 of 66', 'Version 2.0', 'July 5,10', 'Total number of daily tablets of medication for treatment of comorbidities (<2 tablets', 'or >2 tablets)', 'Number of doses of the study drug or comparative drug (once weekly, once daily or', 'twice daily)', 'Changes in the scores per question in the DTR-QOL Questionnaire at each assessment time', 'point.', 'Changes in the scores for per question in the DTSQ at each assessment time point.', '1)', 'Summary statistics for measurements and the changes from the baseline (Week 0) will be', 'calculated per treatment group.', 'Other endpoints>', 'Summarizations below will be performed in the \"full analysis set\" (FAS).', 'Laboratory tests', 'Treatment compliance of each study subject will be calculated and summary statistics of', 'compliance per treatment group will be presented.', 'Treatment compliance', 'Treatment compliance of each study subject will be calculated and summary statistics of', 'compliance per treatment group will be presented.', 'The Basic Information on Study Subject (Your Basic Profile)', 'Frequency of answers to each question at each visit will be analyzed per treatment group.', '13.1.4 Safety analysis', 'Frequency tables will be prepared for the incidences of adverse events, hypoglycemia, and', 'hospitalization for type 2 diabetes (number and duration of hospitalization) after the first', 'administration of the study drug or comparative drug administration in the \"safety population\" in', 'each treatment group.', '13.2', 'Criteria for interim analysis and premature discontinuation', 'No interim analysis is planned.', '13.3', 'Determination of the number of planned study subject', 'In this clinical study, to discuss changes in the total score for all questions in the DTR-QOL', 'Questionnaire from the baseline (Week 0) to the end of the treatment period, as the primary endpoint,', 'mean changes in the daily DPP-4 inhibitor and trelagliptin groups were assumed as 14.4% and', 'CONFIDENTIAL']", "completion": ""}